To test whether HCQ rescues molecular outcomes relevant to AD in cell culture-based phenotypic assays, we examined its effects on lipopolysaccharide (LPS)-induced neuroinflammation, Aβ1-42 clearance, Aβ1-42 toxicity, and Aβ secretion, tau phosphorylation, cell death due to trophic factor withdrawal, and neurite outgrowth and neurogenesis. The gene discussed is MAPT; the disease is Alzheimer disease.